サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1470315

モノクローナル抗体（mAbs）の世界市場機会と戦略（～2033年）

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033
出版日: | 発行: The Business Research Company | ページ情報: 英文 279 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
モノクローナル抗体（mAbs）の世界市場機会と戦略（～2033年）
出版日: 2024年04月16日
発行: The Business Research Company
ページ情報: 英文 279 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のモノクローナル抗体（mAbs）の市場規模は、2018年に1,151億450万米ドルとなり、2023年までCAGR12.0％超で成長しました。

研究開発費の増加

新薬の研究開発に対する世界のバイオ医薬品支出の増加が、この期間の市場成長に貢献しました。欧米諸国における規制負担の増大とコスト抑制の強化により、企業の研究開発の焦点は、がんや希少疾患など投資対効果の高い疾患に対する医薬品や治療薬の開発へとシフトしました。前臨床試験から承認までのバイオ医薬品企業の研究開発費のうち、バイオ医薬品市場の成功に必要なプロセス開発と製造に割り当てられる費用の割合は、フェーズIで13～17％、承認成功率は4～30％とばらつきがあることが分かりました。直近の抗体全体の成功率が22％である場合、研究開発に対するCMCコストの寄与率は17％と決定されました。したがって、医薬品の研究開発費の増加は、研究開発活動への投資と資金の増加につながり、モノクローナル抗体市場を促進しました。

目次

第1章 エグゼクティブサマリー

  • モノクローナル抗体（mAbs）-市場の魅力とマクロ経済情勢

第2章 目次

第3章 見出し一覧

第4章 図表一覧

第5章 レポートの構成

第6章 市場の特徴

  • 一般的な市場の定義
  • 概要
  • モノクローナル抗体（mAbs）市場の定義とセグメンテーション
  • 市場セグメンテーション：供給源別
    • マウス
    • キメラ
    • ヒト化
    • ヒト
  • 市場セグメンテーション：用途別
    • 抗がん剤
    • 免疫学的
    • 感染症
    • 血液疾患
    • その他の用途
  • 市場セグメンテーション：エンドユーザー別
    • 病院
    • 専門センター
    • その他のエンドユーザー

第7章 主要な市場動向

  • 標的療法と併用療法への投資
  • 市場におけるイノベーションと拡大を推進するための市場企業間の戦略的パートナーシップとコラボレーション
  • 治療に革命を起こす研究開発投資
  • イノベーションを加速するための人工知能の統合
  • 新規治療法とバイオシミラーの製品イノベーションによる治療オプションの広がり

第8章 モノクローナル抗体（mAbs）市場- マクロ経済シナリオ

  • COVID-19がモノクローナル抗体（mAbs）市場に与える影響
  • ウクライナ戦争がモノクローナル抗体（mAbs）市場に与える影響
  • 高インフレがモノクローナル抗体（mAbs）市場に与える影響

第9章 世界の市場規模と成長

  • 市場規模
  • 市場成長実績（2018年～2023年）
    • 市場促進要因（2018年～2023年）
    • 市場抑制要因（2018年～2023年）
  • 市場成長予測（2023年～2028年、2033年）
    • 市場促進要因（2023年～2028年）
    • 市場抑制要因（2023年～2028年）

第10章 世界モノクローナル抗体（mAbs）市場セグメンテーション

  • 世界のモノクローナル抗体（mAbs）市場：供給源別、実績と予測（2018年～2023年、2028年、2033年）
  • 世界のモノクローナル抗体（mAbs）市場：用途別、実績と予測（2018年～2023年、2028年、2033年）
  • 世界のモノクローナル抗体（mAbs）市場：エンドユーザー別、実績と予測（2018年～2023年、2028年、2033年）

第11章 モノクローナル抗体（mAbs）市場、地域別および国別の分析

  • 世界のモノクローナル抗体（mAbs）市場：地域別、実績と予測（2018年～2023年、2028年、2033年）
  • 世界のモノクローナル抗体（mAbs）市場：国別、実績と予測（2018年～2023年、2028年、2033年）

第12章 アジア太平洋市場

第13章 西欧市場

第14章 東欧市場

第15章 北米市場

第16章 南米市場

第17章 中東市場

第18章 アフリカ市場

第19章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Johnson & Johnson
    • 会社概要
    • 製品とサービス
    • ビジネス戦略
  • Merck & Co., Inc.
    • 会社概要
    • 製品とサービス
    • ビジネス戦略
    • 財務概要
  • F. Hoffman-La Roche Ltd.
    • 会社概要
    • 製品とサービス
    • ビジネス戦略
    • 財務概要
  • Bristol Myers Squibb
    • 会社概要
    • 製品とサービス
    • ビジネス戦略
    • 財務概要
  • GlaxoSmithKline plc
    • 会社概要
    • 製品とサービス
    • ビジネス戦略
    • 財務実績

第20章 主要な合併と買収

  • Syngene Acquired Stelis Biopharma
  • Merck Acquired Prometheus Biosciences
  • Biocon Biologics Acquired Viatris Inc
  • Incyte Acquired Villaris Therapeutics
  • FUJIFILM Corporation Acquired Atara Biotherapeutics
  • Exelixis Inc. Acquired Gamamabs Pharma SA's AMHR2 Antibody Technology
  • Sanofi Acquired Kymab Group Ltd.
  • Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.
  • Servier Acquired Symphogen A/S
  • Gilead Sciences Acquired Forty Seven
  • True North Acquired Stake In Biocon Biologics

第21章 パイプライン分析

第22章 機会と戦略

  • 2028年の世界モノクローナル抗体（mAbs）市場- 最も新しい機会を提供する国
  • 2028年の世界モノクローナル抗体（mAbs）市場- 最も新しい機会を提供するセグメント
  • 2028年の世界モノクローナル抗体（mAbs）市場- 成長戦略
    • 市場動向に基づく戦略
    • 競合戦略

第23章 モノクローナル抗体市場：結論・提言

  • 結論
  • 推奨事項
    • 製品
    • 場所
    • 価格
    • プロモーション
    • 人々

第24章 付録

目次
Product Code: o&s1060

Monoclonal antibodies (mAbs) are laboratory-produced antibodies that specifically bind to target molecules with high affinity, avidity and specificity. This binding results in inhibition of the target molecule's biological function by blocking its interaction with other receptor proteins or directing its destruction and elimination.

The monoclonal antibodies (mAbs) market consists of sales by entities (organizations, sole traders and partnerships), that produce monoclonal antibodies used to treat various medical conditions including cancer, inflammatory and autoimmune diseases.

The global monoclonal antibodies (mAbs) market was valued at $115,104.5 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 12.0%.

Increase In R&D Expenditure

The growth in global biopharmaceutical spending on research and development of new drugs contributed to the growth of the market during this period. The increased regulatory burden and greater cost containment in western countries led to shift in companies R&D focus to the development of drugs and therapeutics for diseases such as cancer and rare diseases with high return on investment. The percentage of a biopharmaceutical company's R&D out-of-pocket costs from pre-clinical to approval that needs to be allocated to process development and manufacturing for each biopharmaceutical market success was found to vary between 13-17% for Phase I to approval success rates of 4-30%. For the most recent antibody overall success rates of 22%, the CMC cost contribution to R&D was determined as 17%. Therefore, an increase in pharmaceutical R&D expenditure leads to increasing investments and funding for the R&D activities, which drove the monoclonal antibodies market.

Investment in Targeted and Combination Therapy

Companies in the monoclonal antibodies (mAbs) market are investing in targeted and combination therapy, which has been proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, in September 2022, the European Union (EU) granted approval for AstraZeneca's Evusheld (comprising tixagevimab and cilgavimab, previously known as AZD7442). This long-acting antibody combination was authorized for treating COVID-19 in adults and adolescents (aged 12 years and older, weighing at least 40 kg) who do not need supplemental oxygen and face an elevated risk of developing severe COVID-19. Also, in January 2020, European Commission has granted conditional marketing authorization for Polivy(R) (polatuzumab vedotin), in combination with bendamustine plus MabThera(R) (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma.

The global monoclonal antibodies (mAbs) market is concentrated, with a few large player operating in the market. The top ten competitors in the market made up 41.8% of the total market in 2022.

Monoclonal Antibodies (mAbs) Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mAbs) market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies based on local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis

Where is the largest and fastest-growing market for monoclonal antibodies (mAbs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The monoclonal antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider monoclonal antibodies (mAbs) market; and compares it with other markets.

The report covers the following chapters:

  • Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by source, by application and by end-users market.
  • Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the monoclonal antibodies (mAbs) market.
  • Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
  • Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by source, by application and by end-users in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
  • Regional Market Size And Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Key Mergers And Acquisitions - Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
  • Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for monoclonal antibodies (mAbs) providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Scope

Markets Covered:

  • 1) By Source: Murine; Chimeric; Humanized; Human
  • 2) By Application: Anti-Cancer; Immunological; Infectious Diseases; Hematological Disease; Other Applications
  • 3) By End-Users: Hospitals; Specialty Centers; Other End-Users
  • Companies Mentioned: Johnson & Johnson Inc.; Merck & Co., Inc.; F. Hoffman-La Roche Ltd.; Bristol Myers Squibb; GlaxoSmithKline plc
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Brazil; France; Germany; UK; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; monoclonal antibodies (mAbs) indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Monoclonal Antibodies (mAbs) - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Monoclonal Antibodies (mAbs) Market Definition And Segmentations
  • 6.4 Market Segmentation By Source
    • 6.4.1 Murine
    • 6.4.2 Chimeric
    • 6.4.3 Humanized
    • 6.4.4 Human
  • 6.5 Market Segmentation By Application
    • 6.5.1 Anti-Cancer
    • 6.5.2 Immunological
    • 6.5.3 Infectious Disease
    • 6.5.4 Hematological Disease
    • 6.5.5 Other Applications
  • 6.6 Market Segmentation By End-Users
    • 6.6.1 Hospitals
    • 6.6.2 Specialty Centers
    • 6.6.3 Other End-Users

7 Major Market Trends

  • 7.1 Investment in Targeted and Combination Therapy
  • 7.2 Strategic Partnerships And Collaborations Among Market Players To Drive Innovation and Expansion In The Market
  • 7.3 R&D Investments Revolutionizing Treatment
  • 7.4 Integration of Artificial Intelligence for Accelerated Innovation
  • 7.5 Product Innovation In Novel Therapies and Biosimilars Expands Treatment Options

8 Monoclonal Antibodies (mAbs) Market - Macro-Economic Scenario

  • 8.1 COVID-19 Impact On The Monoclonal Antibodies (mAbs) Market
  • 8.2 Impact Of The War In Ukraine On The Monoclonal Antibodies (mAbs) Market
  • 8.3 Impact Of High Inflation On The Monoclonal Antibodies (mAbs) Market

9 Global Market Size and Growth

  • 9.1 Market Size
  • 9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
    • 9.2.1 Market Drivers 2018 - 2023
    • 9.2.2 Market Restraints 2018 - 2023
  • 9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
    • 9.3.1 Market Drivers 2023 - 2028
    • 9.3.2 Market Restraints 2023 - 2028

10 Global Monoclonal Antibodies (mAbs) Market Segmentation

  • 10.1 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 10.2 Global Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 10.3 Global Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Monoclonal Antibodies (mAbs) Market, Regional and Country Analysis

  • 11.1 Global Monoclonal Antibodies (mAbs) Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 11.2 Global Monoclonal Antibodies (mAbs) Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

  • 12.1 Summary
    • 12.1.1 Market Overview
    • 12.1.2 Region Information
    • 12.1.3 Market Information
    • 12.1.4 Background Information
    • 12.1.5 Government Initiatives
    • 12.1.6 Regulations
    • 12.1.7 Regulatory Bodies
    • 12.1.8 Major Associations
    • 12.1.9 Taxes Levied
    • 12.1.10 Corporate Tax Structure
    • 12.1.11 Investments
    • 12.1.12 Major Companies
  • 12.2 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.3 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.4 Asia-Pacific Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.5 Asia-Pacific Monoclonal Antibodies (mAbs) Market: Country Analysis
  • 12.6 China Market
  • 12.7 Summary
    • 12.7.1 Market Overview
    • 12.7.2 Country Information
    • 12.7.3 Market Information
    • 12.7.4 Background Information
    • 12.7.5 Government Initiatives
    • 12.7.6 Regulations
    • 12.7.7 Regulatory Bodies
    • 12.7.8 Major Associations
    • 12.7.9 Taxes Levied
    • 12.7.10 Corporate Tax Structure
    • 12.7.11 Investments
    • 12.7.12 Major Companies
  • 12.8 China Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.9 China Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.10 China Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.11 India Market
  • 12.12 India Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.13 India Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.14 India Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.15 Japan Market
  • 12.16 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.17 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.18 Japan Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.19 Australia Market
  • 12.20 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.21 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.22 Australia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.23 Indonesia Market
  • 12.24 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.25 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.26 Indonesia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.27 South Korea Market
  • 12.28 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.29 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 12.30 South Korea Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

  • 13.1 Summary
    • 13.1.1 Market Overview
    • 13.1.2 Region Information
    • 13.1.3 Market Information
    • 13.1.4 Background Information
    • 13.1.5 Government Initiatives
    • 13.1.6 Regulations
    • 13.1.7 Regulatory Bodies
    • 13.1.8 Major Associations
    • 13.1.9 Taxes Levied
    • 13.1.10 Corporate tax structure
    • 13.1.11 Investments
    • 13.1.12 Major Companies
  • 13.2 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.3 Western Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.4 Western Europe Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.5 Western Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
  • 13.6 UK Market
  • 13.7 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.8 UK Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.9 UK Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.10 Germany Market
  • 13.11 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.12 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.13 Germany Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.14 France Market
  • 13.15 France Monoclonal Antibodies (Mabs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.16 France Monoclonal Antibodies (Mabs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 13.17 France Monoclonal Antibodies (Mabs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

  • 14.1 Summary
    • 14.1.1 Market Overview
    • 14.1.2 Region Information
    • 14.1.3 Market Information
    • 14.1.4 Background Information
    • 14.1.5 Government Initiatives
    • 14.1.6 Regulations
    • 14.1.7 Regulatory Bodies
    • 14.1.8 Major Associations
    • 14.1.9 Taxes Levied
    • 14.1.10 Corporate Tax Structure
    • 14.1.11 Investments
    • 14.1.12 Major Companies
  • 14.2 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.3 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.4 Eastern Europe Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.5 Eastern Europe Monoclonal Antibodies (mAbs) Market: Country Analysis
  • 14.6 Russia Market
  • 14.7 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.8 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 14.9 Russia Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

  • 15.1 Summary
    • 15.1.1 Market Overview
    • 15.1.2 Region Information
    • 15.1.3 Market Information
    • 15.1.4 Background Information
    • 15.1.5 Government Initiatives
    • 15.1.6 Regulations
    • 15.1.7 Regulatory Bodies
    • 15.1.8 Major Associations
    • 15.1.9 Taxes Levied
    • 15.1.10 Corporate Tax Structure
    • 15.1.11 Investments
    • 15.1.12 Major Companies
  • 15.2 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.3 North America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.4 North America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.5 North America Monoclonal Antibodies (mAbs) Market: Country Analysis
  • 15.6 USA Market
  • 15.7 Summary
    • 15.7.1 Market Overview
    • 15.7.2 Country Information
    • 15.7.3 Market Information
    • 15.7.4 Background Information
    • 15.7.5 Government Initiatives
    • 15.7.6 Regulations
    • 15.7.7 Regulatory Bodies
    • 15.7.8 Major Associations
    • 15.7.9 Taxes Levied
    • 15.7.10 Corporate Tax Structure
    • 15.7.11 Investments
    • 15.7.12 Major Companies
  • 15.8 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.9 USA Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 15.10 USA Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

  • 16.1 Summary
    • 16.1.1 Market Overview
    • 16.1.2 Region Information
    • 16.1.3 Market Information
    • 16.1.4 Background Information
    • 16.1.5 Government Initiatives
    • 16.1.6 Regulations
    • 16.1.7 Regulatory Bodies
    • 16.1.8 Major Associations
    • 16.1.9 Taxes Levied
    • 16.1.10 Corporate Tax Structure
    • 16.1.11 Investments
    • 16.1.12 Major Companies
  • 16.2 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.3 South America Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.4 South America Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.5 South America Monoclonal Antibodies (mAbs) Market: Country Analysis
  • 16.6 Brazil Market
  • 16.7 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.8 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 16.9 Brazil Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

  • 17.1 Summary
    • 17.1.1 Market Overview
    • 17.1.2 Region Information
    • 17.1.3 Market Information
    • 17.1.4 Background Information
    • 17.1.5 Government Initiatives
    • 17.1.6 Regulations
    • 17.1.7 Regulatory Bodies
    • 17.1.8 Major Associations
    • 17.1.9 Taxes Levied
    • 17.1.10 Corporate Tax Structure
    • 17.1.11 Investments
    • 17.1.12 Major Companies
  • 17.2 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 17.3 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 17.4 Middle East Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

  • 18.1 Summary
    • 18.1.1 Market Overview
    • 18.1.2 Region Information
    • 18.1.3 Market Information
    • 18.1.4 Background Information
    • 18.1.5 Government Initiatives
    • 18.1.6 Regulations
    • 18.1.7 Regulatory Bodies
    • 18.1.8 Major Associations
    • 18.1.9 Taxes Levied
    • 18.1.10 Corporate Tax Structure
    • 18.1.11 Investment
    • 18.1.12 Major Companies
  • 18.2 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Source, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 18.3 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
  • 18.4 Africa Monoclonal Antibodies (mAbs) Market, Segmentation By End-Users, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape And Company Profiles

  • 19.1 Company Profiles
  • 19.2 Johnson & Johnson
    • 19.2.1 Company Overview
    • 19.2.2 Products And Services
    • 19.2.3 Business Strategy
  • nal overview
  • 19.3 Merck & Co., Inc.
    • 19.3.1 Company Overview
    • 19.3.2 Products And Services
    • 19.3.3 Business Strategy
    • 19.3.4 Financial Overview
  • 19.4 F. Hoffman-La Roche Ltd.
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
    • 19.4.3 Business Strategy
    • 19.4.4 Financial Overview
  • 19.5 Bristol Myers Squibb
    • 19.5.1 Company Overview
    • 19.5.2 Products And Services
    • 19.5.3 Business Strategy
    • 19.5.4 Financial Overview
  • 19.6 GlaxoSmithKline plc
    • 19.6.1 Company Overview
    • 19.6.2 Products And Services
    • 19.6.3 Business Strategy
    • 19.6.4 Financial performance

20 Key Mergers And Acquisitions

  • 20.1 Syngene Acquired Stelis Biopharma
  • 20.2 Merck Acquired Prometheus Biosciences
  • 20.3 Biocon Biologics Acquired Viatris Inc
  • 20.4 Incyte Acquired Villaris Therapeutics
  • 20.5 FUJIFILM Corporation Acquired Atara Biotherapeutics
  • 20.6 Exelixis Inc. Acquired Gamamabs Pharma SA's AMHR2 Antibody Technology
  • 20.7 Sanofi Acquired Kymab Group Ltd.
  • 20.8 Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.
  • 20.9 Servier Acquired Symphogen A/S
  • 20.10 Gilead Sciences Acquired Forty Seven
  • 20.11 True North Acquired Stake In Biocon Biologics

21 Pipeline Analysis

22 Opportunities And Strategies

  • 22.1 Global Monoclonal Antibodies (mAbs) Market In 2028 - Countries Offering Most New Opportunities
  • 22.2 Global Monoclonal Antibodies (mAbs) Market In 2028 - Segments Offering Most New Opportunities
  • 22.3 Global Monoclonal Antibodies (mAbs) Market In 2028 - Growth Strategies
    • 22.3.1 Market Trend Based Strategies
    • 22.3.2 Competitor Strategies

23 Monoclonal Antibodies Market, Conclusions And Recommendations

  • 23.1 Conclusions
  • 23.2 Recommendations
    • 23.2.1 Product
    • 23.2.2 Place
    • 23.2.3 Price
    • 23.2.4 Promotion
    • 23.2.5 People

24 Appendix

  • 24.1 Geographies Covered
  • 24.2 Market Data Sources
  • 24.3 Research Methodology
  • 24.4 Currencies
  • 24.5 The Business Research Company
  • 24.6 Copyright and Disclaimer